StockNews.com upgraded shares of Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) from a hold rating to a buy rating in a report published on Tuesday. A number of other equities research analysts have also commented on PRTK. BTIG Research reduced their price target on Paratek Pharmaceuticals from $24.00 to $5.00 in a research report on Tuesday, […]